[Olanzapine: preclinical pharmacology and recent findings].
Moore
N
N
Lilly Research Center, Eli Lilly & Co., Windlesham, Surrey, UK.
D000818:Animals; D014150:Antipsychotic Agents / Q000378:metabolism / Q000494:pharmacology; D001362:Avoidance Learning / Q000187:drug effects; D001569:Benzodiazepines; D002375:Catalepsy / Q000139:chemically induced; D003216:Conditioning, Operant / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D006801:Humans; D016202:N-Methylaspartate / Q000037:antagonists & inhibitors; D000077152:Olanzapine; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D011712:Pyramidal Tracts / Q000187:drug effects; D011941:Receptors, Adrenergic / Q000378:metabolism; D011954:Receptors, Dopamine / Q000378:metabolism; D011976:Receptors, Muscarinic / Q000378:metabolism; D011985:Receptors, Serotonin / Q000378:metabolism
D014150:Antipsychotic Agents; D011941:Receptors, Adrenergic; D011954:Receptors, Dopamine; D011976:Receptors, Muscarinic; D011985:Receptors, Serotonin; D001569:Benzodiazepines; D010890:Pirenzepine; D016202:N-Methylaspartate; D000077152:Olanzapine